Zacks Investment Research upgraded shares of Amedisys (NASDAQ:AMED) from a hold rating to a buy rating in a report published on Tuesday morning. Zacks Investment Research currently has $57.00 target price on the health services provider’s stock.

According to Zacks, “Over the past year, Amedisys has been trading above the broader industry. The company is currently exploring new opportunities in both Home Health and Hospice. At the Home Health division, the company witnessed a decline in Medicare revenues, while there was an improvement in non-Medicare revenues. At the Hospice division, the company registered strong growth across all segments. A favorable demographic trend and strategic acquisitions bode well for the company. On the flip side, escalating operating expenses and declining gross margin continue to raise concerns. Also, an intense competitive landscape and regulatory concerns continue to pose challenges in the home health and hospice industry.”

Several other brokerages have also commented on AMED. Benchmark upgraded Amedisys from a hold rating to a buy rating and set a $56.00 price target on the stock in a research note on Thursday, November 2nd. William Blair restated an outperform rating on shares of Amedisys in a research note on Tuesday, November 21st. Royal Bank of Canada restated a sector perform rating and set a $62.00 price target (up previously from $56.00) on shares of Amedisys in a research note on Thursday, November 9th. SunTrust Banks restated a buy rating and set a $60.00 price target on shares of Amedisys in a research note on Monday, October 9th. Finally, Craig Hallum restated a buy rating and set a $68.00 price target (up previously from $55.00) on shares of Amedisys in a research note on Thursday, November 9th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of $60.64.

Amedisys (NASDAQ:AMED) opened at $56.40 on Tuesday. The company has a market capitalization of $1,905.89, a price-to-earnings ratio of 45.12, a PEG ratio of 1.17 and a beta of 0.73. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.33 and a current ratio of 1.33. Amedisys has a 52 week low of $45.60 and a 52 week high of $65.91.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Suntrust Banks Inc. grew its stake in Amedisys by 4.3% in the second quarter. Suntrust Banks Inc. now owns 5,702 shares of the health services provider’s stock valued at $358,000 after purchasing an additional 237 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in Amedisys by 1.9% in the second quarter. The Manufacturers Life Insurance Company now owns 22,348 shares of the health services provider’s stock valued at $1,404,000 after purchasing an additional 410 shares during the last quarter. California Public Employees Retirement System grew its stake in Amedisys by 1.1% in the second quarter. California Public Employees Retirement System now owns 62,300 shares of the health services provider’s stock valued at $3,913,000 after purchasing an additional 700 shares during the last quarter. Systematic Financial Management LP grew its stake in Amedisys by 3.3% in the fourth quarter. Systematic Financial Management LP now owns 29,850 shares of the health services provider’s stock valued at $1,573,000 after purchasing an additional 945 shares during the last quarter. Finally, American International Group Inc. grew its stake in Amedisys by 6.0% in the third quarter. American International Group Inc. now owns 22,560 shares of the health services provider’s stock valued at $1,262,000 after purchasing an additional 1,285 shares during the last quarter. Institutional investors own 94.97% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.watchlistnews.com/amedisys-amed-upgraded-to-buy-by-zacks-investment-research/1856093.html.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.